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726 LETTERS TO THE EDITOR
Dr Wilson replies:
Sir - Dr Salmon and his colleagues suggest that the
demonstration of assay comparability using cell
lines does not necessarily indicate assay
comparability when human tumour biopsy material
is used. Reasons underlying this suggestion include
the high plating efficiencies of established cell lines,
and the potential differences in chemosensitivity
between clonogenic and non-clonogenic cells.
Results obtained using cell lines were not
considered to be totally irrelevant since the oft-
quoted comparative study which favoured
clonogenic assays over cytotoxicity assays utilised
highly clonogenic T1 lymphoma cells (Roper &
Drewinko, 1976). It is clearly necessary that
cytotoxicity assays should give reproducible dose-
response curves, and the present study differed
from Roper and Drewinko's in that both
cytotoxicity and clonogenic assays fulfilled this
criterion. Validation of an assay technique with a
defined cell population is an essential stage prior to
extrapolation to its use with human biopsy
material, as is demonstration of comparability
between assays, and the present study showed that
both clonogenic and cytotoxicity assays have the
potential to give the same results, a point which
had not previously been demonstrated.
Additionally, the cell lines were chosen to have low
plating efficiencies (1-1%), which were similar to
the higher values obtained with human tumours.
Although prospective studies are the ultimate test
for in vitro predictive assays, retrospective
correlations are a necessary preliminary for
validation of an assay, and it is noteworthy that
both cytotoxicity and clonogenic assays have given
the same levels of positive correlation for sensitivity
and resistance. This leads to the supposition that
assays should give comparable results with biopsy
material, and it is agreed that this needs
confirming. Evidence favouring the conclusion is
now to be found in the literature, in reports
demonstrating good correlation between a
clonogenic assay and a 4-day 3H-thymidine
incorporation assay (Friedman & Glaubiger, 1982;
Tanigawa et al., 1982) using human tumour biopsy
material.
There is currently no evidence to suggest that
clonogenic and non-clonogenic cells do differ in
chemosensitivity, and the in vitro results described
above suggest that this is not so. Additionally
clinical data from patients treated on the basis of
clonogenic assay results indicates shared
chemosensitivity.
A large proportion of correlations with the
clonogenic assay have been done in heavily pre-
treated patients, who are likely to have a large
tumour burden at inception of chemotherapy on
the basis of assay results. In such patients the
putative stem cell or clonogenic fraction represents
only a small percentage of the total proliferating
compartment. Therefore a large proportion of cells
will continue to divide after chemotherapy, and it is
likely that lethal tumour burden will be attained
before these cells reach the end of their finite life
span. The patient will therefore die before gaining
any benefit from the demise of her clonogenic cells
and without showing a clinical response. If the
clonogenic assay predicts resistance the patient
would again die because she would receive no
chemotherapy, although a response could
theoretically be obtained if it is assumed that the
non-clonogenic population is chemosensitive. The
other possibility is that of chemosensitivity in both
populations but not to the same drugs. In this
event, cure could only be achieved if the patient
were to be treated on the basis of both clonogenic
and non-clonogenic assays. It is noteworthy that
patients treated on the basis of clonogenic assays do
attain a response, implying that a proportion of
cells exceeding the clonogenic compartment are
killed. There are two arguments therefore, (i) if
clonogenic chemosensitivity does not equal non-
clonogenic sensitivity then both assay results must
be accepted to ensure adequate treatment in
patients with bulky disease, (ii) if clonogenic
chemosensitivity does equal non-clonogenic
chemosensitivity then either assay method is valid.
In quoting negative reports on the "Hamburger-
Salmon" system it was not the authors' intention to
repudiate the potential value of clonogenic assays
but to point out that problems do exist with the
assay system, and that non-clonogenic assays also
have an important role in in vitro predictive testing.
Yours etc.
A.P. Wilson,
Department of Reproductive Pathology
St Mary's Hospital
Manchester M13 OJH
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